Skip to main content
SpringerLink
Log in

Pulmonary antihypertensives in paeds, previously unreported AEs

  • Review
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. see Reactions 1418 p2; 801161297

Reference

  • Maxey DM, et al. Food and Drug Administration (FDA) Postmarket Reported Side Effects and Adverse Events Associated with Pulmonary Hypertension Therapy in Pediatric Patients. Pediatric Cardiology : [9 pages], 27 Mar 2013. Available from: URL: http://dx.doi.org/10.1007/s00246-013-0688-2

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pulmonary antihypertensives in paeds, previously unreported AEs. Reactions Weekly 1447, 4 (2013). https://doi.org/10.1007/s40278-013-2371-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-013-2371-z

Search

Navigation